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Linezolid has most commonly been associated with myelo-
suppression, peripheral neuropathy, optic neuropathy, and
serotonin syndrome, particularly in those with prolonged
durations of use (>28 days).1,2 Epileptic seizures are extremely
rare. The case of an elderly patient without epilepsy who
developed complex partial seizures on day 36 of linezolid
treatment is reported below.
A 68-year-old female was admitted 4 months after an
accidental fall due to progressive difﬁculty walking. Spinal
magnetic resonance imaging (MRI) revealed depressed fractures
complicated with spondylodiscitis involving the level 10 and
11 thoracic vertebrae. Cultures obtained from the involved bone
and soft tissues yielded methicillin-resistant Staphylococcus aureus
(MRSA). She had mild leukocytosis and a markedly elevated C-
reactive protein (CRP) level, while liver and kidney function were
normal. Intravenous linezolid 600 mg every 12 h was initiated.
On day 36 of treatment, she developed a ‘complex partial seizure’,
so far unique for her, with eyes ﬁxed and deviated to the left
side, unresponsiveness to verbal stimuli, and without concomitant
motor autonomic symptoms. This seizure lasted for around
15 min. Results of arterial blood gas and biochemistry analyses
obtained soon after the seizure revealed no ﬁndings of metabolic
acidosis or any electrolyte imbalance, including lactate, sodium,
and potassium. No signiﬁcant ﬁndings were detected on cranial
MRI, however her awake and sleep electroencephalography
(EEG) was compatible with postictal period on day 3 after the
seizure. An EEG obtained 35 days after the seizure was essentially
normal. A 1-hour sleep EEG was normal. She was taking no
concomitant medications that could have contributed to the
seizure activity.
Linezolid was discontinued immediately and the treatment was
switched to intravenous daptomycin 6 mg/kg/day. No antiepileptic
treatment was initiated and no more seizures or other neurological
ﬁndings developed during follow-up.
To our knowledge, this is the ﬁrst case of linezolid-induced
seizures in a patient with no known epilepsy.3,4 The long-term
use of linezolid may induce an epileptic seizure even in thosehttp://dx.doi.org/10.1016/j.ijid.2015.05.007
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).without epilepsy. Withdrawal of the drug may be sufﬁcient as a
measure.
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